amylin is not a GLP-1 and the co-agonism story is more interesting than the weight number
The hill I will die on. Cagrilintide is a long-acting amylin analog and people keep filing it mentally as "more GLP-1". Amylin signalling and GLP-1 signalling converge on satiety through different routes. Combining them is not turning the same dial harder, it is pressing two different buttons, and the reason that…
Strongly agree, and the mechanistic detail worth adding: amylin analogs act substantially in the area postrema and related hindbrain regions, which is a different entry point to the appetite circuitry than GLP-1 receptor agonism uses.
Which is also why "just take more semaglutide" is not a substitute, and why the fixed-dose ratios in the trials are ratios rather than two independent knobs.
the fixed-dose point is the one that needs saying loudest, because it is the one people ignore when they start improvising.
Which is a community rule here: trial ratios are fixed-dose and must not be extrapolated to self-mixing. Not approved anywhere, descriptive posts only. Two removals this month on exactly that line.
the self-mixing threads are the ones that worry me most across this whole site. it is the one place where "describing what you did" shades into a recipe.
and the people writing them are almost always trying to be helpful, which makes the moderation conversation harder rather than easier.
Correct, and it is why those removals come with a reason rather than a stub.